Altimmune Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	0.03	0.04	0.02	0.43	-0.07	4.41
Revenue Growth	55.00%	105.00%	-95.30%	-	-	-46.12%
Cost of Revenue	66.72	66.43	82.23	65.8	70.45	73.84
Gross Profit	-66.69	-66.39	-82.21	-65.37	-70.52	-69.43
Selling, General & Admin	32.04	28.1	20.97	18.14	17.13	15.41
Operating Expenses	32.04	28.1	20.97	18.14	17.13	15.41
Operating Income	-98.73	-94.49	-103.17	-83.51	-87.65	-84.84
Interest Expense	-3.54	-1.64	-0.01	-0.04	-0.01	-0.01
Interest & Investment Income	12.29	7.54	8.07	7.35	2.87	0.2
Other Non Operating Income (Expenses)	-0.29	-0.19	0.05	0.17	-0.03	-0.37
EBT Excluding Unusual Items	-90.27	-88.77	-95.06	-76.03	-84.82	-85.02
Asset Writedown	-1.49	-	-	-12.42	-	-11.37
Other Unusual Items	-	-	-	-	-0.09	-0.7
Pretax Income	-91.76	-88.77	-95.06	-88.45	-84.91	-97.09
Income Tax Expense	-	-0.68	-	-	-0.2	-
Net Income	-91.76	-88.09	-95.06	-88.45	-84.71	-97.09
Net Income to Common	-91.76	-88.09	-95.06	-88.45	-84.71	-97.09
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	126	88	71	53	47	41
Shares Outstanding (Diluted)	126	88	71	53	47	41
Shares Change	68.90%	24.08%	33.35%	13.47%	13.67%	61.03%
EPS (Basic)	-0.73	-1.00	-1.34	-1.66	-1.81	-2.35
EPS (Diluted)	-0.73	-1.00	-1.34	-1.66	-1.81	-2.35
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-76.56	-67.55	-79.85	-75.86	-62.71	-90.36
Free Cash Flow Per Share	-0.61	-0.77	-1.13	-1.43	-1.34	-2.19
Operating Margin	-318493.55%	-230460.98%	-515860.00%	-19603.29%	-	-1923.90%
Profit Margin	-296000.00%	-214860.98%	-475295.00%	-20762.21%	-	-2201.59%
Free Cash Flow Margin	-246974.19%	-164746.34%	-399240.00%	-17806.81%	-	-2048.87%
EBITDA	-98.63	-94.38	-102.93	-83.03	-87.16	-84.29
D&A For EBITDA	0.1	0.11	0.24	0.48	0.49	0.55
EBIT	-98.73	-94.49	-103.17	-83.51	-87.65	-84.84

SEC Filings: 10-K · 10-Q